Altamira Therapeutics (CYTO) Issues Year-End 2022 Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Altamira Therapeutics Provides Year-End 2022 Business Update
December 19, 2022 8:47 AM ESTHamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) --
Altamira Therapeutics Provides Year-End 2022 Business Update
Strategic BentrioTM partnering or divestiture process enters decisive phasePartnering or divestiture process for inner ear therapeutics assets ongoingImplementing new organizational structure to support strategic focus on RNA businessPromoted Covadonga Pañeda, Ph.D., from Chief Development Officer to Chief Operating OfficerDatabase about to be locked in... More